Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Phase 1 progress for Actimab-A
January 2016
SHARING OPTIONS:

NEW YORK—Encouraging data from the Phase 1 portion of Actinium Pharmaceuticals Inc.’s Phase 1/2 clinical trial of Actimab-A were shared at the 57th American Society of Hematology Annual Meeting. Actimab-A is being studied in acute myeloid leukemia (AML) patients over the age of 60 that have not received prior therapy and have declined or are unsuitable for intensive induction chemotherapy. In this study, eight of 11 patients evaluated (73 percent) had mean bone marrow blast reduction of 72 percent. Four of 14 patients (29 percent) presented with objective responses after one cycle of therapy with one patient achieving complete remission, two patients achieving complete remission with incomplete platelet count recovery and one patient achieving complete remission with incomplete blood count recovery.
 
“The rate of remission and tolerability results seen with Actimab-A in this trial are very encouraging, as elderly patients diagnosed with AML have limited options and prognosis is typically poor,” said Dr. Joseph Jurcic, study investigator at Columbia University Medical Center.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.